Alzheimer’s Drug Discovery Foundation (ADDF) - LOI

* ADDF/Belfer ApoE Therapeutics Innovation Program: funding for pre-clinical programs: $300K over 1 - 2 years. Funding for clinical trials of novel agents such as phase 1b or 2a studies employing biomarkers as outcome measures: up to $1,000,000.
* ADDF/Charles River RFP: Use of Aged Rats as a Relevant Preclinical Model for the Development of Therapeutics for Cognitive Aging and Alzheimer’s Disease. High priority interests for this RFP include: 1) Testing of novel compounds and targets proposed to be associated with age-related neurodegeneration and impairment in cognition and behavior; 2) employing novel outcome measures and/or biomarkers in the aged rat model. Funding: up to $150K for 1 year.
* PACT RFP: the goal of the RFP is to increase the number of innovative drugs tested in humans for Alzheimer’s disease. This program will fund biomarker-based pilot clinical trials for Alzheimer’s disease. Funding: up to $1,000,000 per application.